Defensin HNP-1
Overview
Human neutrophil peptide 1 (HNP-1) is a 30-amino acid alpha-defensin produced by neutrophils as part of the innate immune response. It contains three stabilizing disulfide bonds and forms amphipathic structures that disrupt microbial membranes through electrostatic and hydrophobic interactions. HNP-1 exhibits antimicrobial activity against bacteria, fungi, and enveloped viruses, and also modulates immune cell function and inflammatory responses. As an endogenous peptide, it has been studied for potential therapeutic augmentation in immunocompromised states and chronic infections.
Key Research Findings
Preclinical studies have characterized HNP-1 antimicrobial mechanisms and immunomodulatory properties in vitro and in animal models. Elevated or reduced HNP-1 levels have been associated with various infectious and inflammatory diseases in observational clinical studies. No therapeutic clinical trials using exogenous HNP-1 administration have been conducted, and development challenges include synthesis cost and delivery optimization.
Topical, Intravenous
Research Phase
Interested in Defensin HNP-1?
Find a verified provider experienced with Defensin HNP-1 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Defensin HNP-1 ProviderRelated Peptides
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fusion step. Enfuvirtide binds to the first heptad repeat (HR1) region of gp41, preventing the conformational change required for viral-cell membrane fusion. It is the first and only FDA-approved fusion inhibitor and is active against HIV-1 strains resistant to other antiretroviral drug classes.
Magainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells. Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens.
Pexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic stability. It disrupts bacterial membranes through electrostatic interaction and pore formation, demonstrating broad-spectrum activity against gram-positive and gram-negative organisms, including methicillin-resistant Staphylococcus aureus. Pexiganan was developed as a topical agent for infected diabetic foot ulcers, leveraging its rapid bactericidal action and low resistance potential. Structural modifications from the parent magainin sequence improve its pharmacological profile for clinical use.
Omiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses. Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices.